InterMune, Inc. (NASDAQ:

) continues to skyrocket higher, gaining 134% to $34.33, a gain of $20.06 per shares. The company received a positive opinion from the EMA for Pirfenidone / positive opinion for approval of Esbriet in EU. Wedbush put a $55 price target on the name, and Canaccord Genuity has a price target of $38. Oppenheimer was also positive on the name. The Committee for Medicinal Products for Human Use (

) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a marketing authorization for Esbriet (pirfenidone) in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis. This opinion came earlier than expected for ITMN.